Cabazitaxel.
Galsky
Matthew D
MD
Mount Sinai School of Medicine, Box 1079, One Gustave L. Levy Place, New York, New York 10029-6574, USA. matthew.galsky@mssm.edu
Dritselis
Argyris
A
Kirkpatrick
Peter
P
Oh
William K
WK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D055808:Drug Discovery; D006801:Humans; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D043823:Taxoids / Q000008:administration & dosage; D014481:United States; D014486:United States Food and Drug Administration
D043823:Taxoids; C552428:cabazitaxel; D011241:Prednisone
Lancet. 2010 Apr 24;375(9724):1437-46
20398925
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Cancer Res. 2008 Jun 1;68(11):4447-54
18519708
J Clin Oncol. 2010 Mar 20;28(9):1496-501
20159814
N Engl J Med. 2010 Jul 29;363(5):411-22
20818862
Nat Rev Cancer. 2004 Apr;4(4):253-65
15057285
Science. 2009 May 8;324(5928):787-90
19359544
Cancer Res. 2008 Aug 1;68(15):6407-15
18676866
Nat Clin Pract Oncol. 2008 Sep;5(9):506-7
18648352
J Clin Oncol. 2010 Mar 20;28(9):1489-95
20159823
Ann Oncol. 2008 Sep;19(9):1547-52
18436520
Nat Rev Drug Discov. 2010 Jul;9(7):513-4
20592741
Clin Cancer Res. 2009 Jan 15;15(2):723-30
19147780